Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis

被引：59

作者：

Mathew, Veena ^{[1
]}

Wang, Annabel K. ^{[1
,2
]}

机构：

[1] Univ Calif Irvine, Dept Neurol, UCI ALS & Neuromuscular Ctr, Orange, CA 92668 USA

[2] Tibor Rubin VA Med Ctr, Neurol Sect, Long Beach, CA USA

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2019年 / 13卷

关键词：

antisense oligonucleotide; familial amyloid polyneuropathy; Inotersen; mRNA; RNase H; ANTISENSE OLIGONUCLEOTIDE; LIVER-TRANSPLANTATION; MOLECULAR-MECHANISMS; POLYNEUROPATHY; DIFLUNISAL; THERAPY; GENE;

D O I：

10.2147/DDDT.S162913

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Hereditary transthyretin amyloidosis is a fatal autosomal dominant disorder characterized by deposition of transthyretin amyloid into the peripheral nervous system, heart, kidney, and gastrointestinal tract. Previous treatments using liver transplantation and small molecule stabilizers were not effective in stopping disease progression. Inotersen, a 2'-O-methyoxyethyl-modified antisense oligonucleotide, which acts by reducing the production of transthyretin, was recently demonstrated to improve disease course and quality of life in early hereditary transthyretin amyloidosis polyneuropathy in a 15-month Phase III study.

引用

页码：1515 / 1525

页数：11

共 50 条

[31] INOTERSEN ON NEUROPATHY SYMPTOM AND CHANGE SCORES IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS: SUBGROUPS AND RESPONDER ANALYSES
Yarlas, Aaron
Lovley, Andrew
Brown, Duncan
Llonch, Montserrat Vera
Khella, Sami
Karam, Chafic
Dyck, P. James
MUSCLE & NERVE, 2021, 64 : S59 - S59
[32] Safety and Efficacy of Inotersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (NEURO-TTR)
Gertz, Morie
Wang, Annabel K.
Coelho, Teresa
Cruz, Marcia Waddington
Polydefkis, Michael J.
Dyck, Peter J.
Scheinberg, Morton
Plante-Bordeneuve, Violaine
Berk, John
Barroso, Fabio
Adams, David
Brannagan, Thomas
Whelan, Carol
Merlini, Giampaolo
Drachman, Brian M.
Heitner, Stephen B.
Conceicao, Isabel
Schmidt, Harmut
Vita, Giuseppe
Campistol, Josep M.
Gamez, Josep
Gane, Edward
Gorevic, Peter
Oliveira, Acary Souza Bulle
Monia, Brett P.
Hughes, Steven G.
Kwoh, Jesse
McEvoy, Bradley W.
Baker, Brenda F.
Ackermann, Elizabeth J.
Benson, Merrill D.
NEUROLOGY, 2018, 90
[33] SAFETY AND EFFICACY OF INOTERSEN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS WITH POLYNEUROPATHY (NEURO-TTR)
Gertz, Morie
Wang, Annabel
Cruz, Marcia Waddington
Polydefkis, Michael
Dyck, Peter
Scheinberg, Morton
Berk, John
Barroso, Fabio
Brannagan, Thomas
Drachman, Brian
Heitner, Stephen
Gorevic, Peter
Monia, Brett
Benson, Merrill
MUSCLE & NERVE, 2018, 58 : S55 - S55
[34] Treatment success in hereditary transthyretin amyloidosis
Ian Fyfe
Nature Reviews Neurology, 2018, 14 : 509 - 509
[35] COST OF INOTERSEN AND PATISIRAN FOR THE TREATMENT OF ADULTS WITH POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN CANADA, GERMANY, AND ITALY
Brown, D.
Vera-Llonch, M.
Shaff, M.
Rolli, A.
Vega, M.
Blum, M.
Nestler-Parr, S.
Jiresch, M.
Weycker, D.
VALUE IN HEALTH, 2020, 23 : S606 - S607
[36] Long-term Treatment with Inotersen for Amyloid Transthyretin Amyloidosis Cardiomyopathy
Dasgupta, Noel
Benson, Merrill
JOURNAL OF CARDIAC FAILURE, 2018, 24 (08) : S59 - S59
[37] Hereditary Transthyretin-mediated Amyloidosis Now new on the German Pharmaceutical Market: EU-Approval of Tegsedi (Inotersen)
不详
VISCERAL MEDICINE, 2018, 34 (04) : 321 - 321
[38] Progressive vitreous deposits during treatment with inotersen for hereditary ATTR amyloidosis
Marques, Joao Heitor
Coelho, Joao
Meneres, Maria Joao
Beirao, Joao Melo
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2021, 28 (04): : 275 - 276
[39] Treatment Updates for Neuropathy in Hereditary Transthyretin Amyloidosis
King, Deandre
Lau, K. H. Vincent
Kaku, Michelle C.
CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2023, 25 (06) : 137 - 149
[40] Advances in the treatment of hereditary transthyretin amyloidosis: A review
Gertz, Morie A.
Mauermann, Michelle L.
Grogan, Martha
Coelho, Teresa
BRAIN AND BEHAVIOR, 2019, 9 (09):

← 1 2 3 4 5 →